FindTrial
Sign In

Arterial embolization by NK939 for hypervascular tumors and arteriovenous malformations

Arterial embolization by NK939 for hypervascular tumors and arteriovenous malformations

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221247
Enrollment
25
Registered
2010-09-22
Start date
2010-09-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypervascular tumors or arteriovenous malformations

Interventions

investigational material(s) Generic name etc : NK939 INN of investigational material : Therapeutic category code : 332 Hemostatics Dosage and Administration for Investigational material : Intraarteri

Sponsors

Nippon Kayaku Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who are clinically diagnosed as having hypervascular tumors or arteriovenous malformations.

Exclusion criteria

Exclusion criteria: In large diameter arteriovenous shunts

Design outcomes

Primary

MeasureTime frame
Embolize or marked blood flow reduction to the artery Success rate of embolization—

Secondary

MeasureTime frame
Clinical effect—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026